Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781295 | 0.99 | NPC1 (0.46) | NPC1RAB9ACHUKTXNRD1NOX4 | |
| SCHEMBL5780241 | 0.92 | CNR1 (0.49) | NPC1RAB9ACHUKTXNRD1NOX4 | |
| SCHEMBL5781631 | 0.88 | BCHE (0.44) | KDRCNR1CNR2 | |
| SCHEMBL5778289 | 0.84 | CNR1 (0.44) | SMN1; SMN2KDRCNR1CNR2 | |
| SCHEMBL5780936 | 0.82 | CNR1 (0.48) | KDRCNR1CNR2 | |
| SCHEMBL5781315 | 0.82 | MKNK2 (0.50) | MAPK1L3MBTL1KDRCNR1CNR2 | |
| SCHEMBL5778390 | 0.81 | FLT1 (0.45) | KDRCNR1CNR2 | |
| SCHEMBL5779693 | 0.81 | NPC1 (0.50) | NPC1RAB9ACHUKTXNRD1NOX4 | |
| SCHEMBL5781112 | 0.80 | FLT1 (0.48) | KDRCNR1CNR2 | |
| SCHEMBL5781215 | 0.78 | L3MBTL1 (0.46) | L3MBTL1KDRCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339710-B1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2006-03-01 | — | — | EP | claimed |
| US-6930118-B2 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | AMRAD OPERATIONS PTY. LTD. (AU) | 2005-08-16 | — | — | US | claimed |
| EP-1339710-A4 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2004-05-12 | — | — | EP | claimed |
| US-20040034073-A1 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | AMRAD OPERATIONS PTY. LTD. (AU) | 2004-02-19 | — | — | US | claimed |
| EP-1339710-A1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | Amrad Operations Pty.,Ltd. (AU) | 2003-09-03 | — | — | EP | claimed |
| WO-2002036590-A1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2002-05-10 | — | — | WO | claimed |
| EP-1339710-B1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2006-03-01 | — | — | EP | disclosed |
| US-6930118-B2 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | AMRAD OPERATIONS PTY. LTD. (AU) | 2005-08-16 | — | — | US | disclosed |
| EP-1339710-A4 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2004-05-12 | — | — | EP | disclosed |
| US-20040034073-A1 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | AMRAD OPERATIONS PTY. LTD. (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1339710-A1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | Amrad Operations Pty.,Ltd. (AU) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036590-A1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034073-A1 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | CNR1, CNR2, OPRK1 | NPC1 1737/4885RAB9A 2178/4885CHUK 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.